Literature DB >> 25213701

Detection of human papillomavirus (HPV) DNA prevalence and p53 codon 72 (Arg72Pro) polymorphism in prostate cancer in a Greek group of patients.

Vasiliki Michopoulou1, Stavros P Derdas, Emmanouil Symvoulakis, Nikolaos Mourmouras, Alexandros Nomikos, Dimitris Delakas, George Sourvinos, Demetrios A Spandidos.   

Abstract

Prostate cancer is the most common neoplasm found in males and the second most frequent cause of cancer-related mortality in males in Greece. Among other pathogens, the detection frequency of human papillomavirus (HPV) has been found to be significantly increased in tumor tissues among patients with sexually transmitted diseases (STDs), depending on the geographical distribution of each population studied. The present study focused on the detection of HPV and the distribution of Arg72Pro p53 polymorphism in a cohort of healthy individuals, as well as prostate cancer patients. We investigated the presence of HPV in 50 paraffin-embedded prostate cancer tissues, as well as in 30 physiological tissue samples from healthy individuals by real-time PCR. Furthermore, the same group of patients was also screened for the presence of the Arg72Pro polymorphism of the p53 gene, a p53 polymorphism related to HPV. Out of the 30 control samples, only 1 was found positive for HPV (3.33 %). On the contrary, HPV DNA was detected in 8 out of the total 50 samples (16 %) in the prostate cancer samples. The distribution of the three genotypes, Arg/Arg, Arg/Pro, and Pro/Pro, was 69.6, 21.7, and 8.7 % in the cancer patients and 75.0, 17.86, and 7.14 % in healthy controls, respectively. No statistically significant association was observed between the HPV presence and the age, stage, p53 polymorphism status at codon 72, or PSA. The increased prevalence of HPV detected in the prostate cancer tissues is in agreement with that reported in previous studies, further supporting the association of HPV infection and prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25213701     DOI: 10.1007/s13277-014-2604-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  58 in total

1.  TP53 Arg72Pro polymorphism and endometrial cancer risk: a meta-analysis.

Authors:  De-Ke Jiang; Lei Yao; Wei-Hua Ren; Wen-Zhang Wang; Bo Peng; Long Yu
Journal:  Med Oncol       Date:  2010-06-15       Impact factor: 3.064

2.  The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR.

Authors:  A M de Roda Husman; J M Walboomers; A J van den Brule; C J Meijer; P J Snijders
Journal:  J Gen Virol       Date:  1995-04       Impact factor: 3.891

Review 3.  Overview of prostate anatomy, histology, and pathology.

Authors:  Christine H Lee; Oluyemi Akin-Olugbade; Alexander Kirschenbaum
Journal:  Endocrinol Metab Clin North Am       Date:  2011-09       Impact factor: 4.741

4.  p53 codon 72 polymorphism and its association with bladder cancer.

Authors:  Nikolaos Soulitzis; George Sourvinos; Despina N Dokianakis; Demetrios A Spandidos
Journal:  Cancer Lett       Date:  2002-05-28       Impact factor: 8.679

5.  Sexual factors and the risk of prostate cancer.

Authors:  K A Rosenblatt; K G Wicklund; J L Stanford
Journal:  Am J Epidemiol       Date:  2001-06-15       Impact factor: 4.897

6.  Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk.

Authors:  J L Stanford; J J Just; M Gibbs; K G Wicklund; C L Neal; B A Blumenstein; E A Ostrander
Journal:  Cancer Res       Date:  1997-03-15       Impact factor: 12.701

7.  TP53 codon 72 polymorphism and colorectal cancer susceptibility: a meta-analysis.

Authors:  Jing-Jun Wang; Yuan Zheng; Liang Sun; Li Wang; Peng-Bo Yu; Jian-Hua Dong; Lei Zhang; Jing Xu; Wei Shi; Yu-Chun Ren
Journal:  Mol Biol Rep       Date:  2010-12-08       Impact factor: 2.316

8.  GP5+/6+ SYBR Green methodology for simultaneous screening and quantification of human papillomavirus.

Authors:  Melissa Rodrigues de Araujo; Laura De Marco; Carlos F Santos; Izabel Regina Fisher Rubira-Bullen; Guglielmo Ronco; Ilenia Pennini; Loredana Vizzini; Franco Merletti; Anna Gillio-Tos
Journal:  J Clin Virol       Date:  2009-05-17       Impact factor: 3.168

9.  Prostate cancer risk and serologic evidence of human papilloma virus infection: a population-based case-control study.

Authors:  Hans-Olov Adami; Hannah Kuper; Swen-Olof Andersson; Reinhold Bergström; Joakim Dillner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-09       Impact factor: 4.254

10.  The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53.

Authors:  M Scheffner; J M Huibregtse; R D Vierstra; P M Howley
Journal:  Cell       Date:  1993-11-05       Impact factor: 41.582

View more
  9 in total

1.  Association between human papillomavirus and prostate cancer: A meta-analysis.

Authors:  Binbin Yin; Weiwei Liu; Pan Yu; Chunhua Liu; Yue Chen; Xiuzhi Duan; Zhaoping Liao; Yuhua Chen; Xuchu Wang; Xiaoyan Pan; Zhihua Tao
Journal:  Oncol Lett       Date:  2017-06-09       Impact factor: 2.967

Review 2.  Multiple pathogens and prostate cancer.

Authors:  James S Lawson; Wendy K Glenn
Journal:  Infect Agent Cancer       Date:  2022-05-30       Impact factor: 3.698

Review 3.  Extracellular MicroRNA in liquid biopsy: applicability in cancer diagnosis and prevention.

Authors:  Alberto Izzotti; Stefano Carozzo; Alessandra Pulliero; Dinara Zhabayeva; Jean Louis Ravetti; Rakhmet Bersimbaev
Journal:  Am J Cancer Res       Date:  2016-07-01       Impact factor: 6.166

4.  Worldwide Prevalence of Human Papillomavirus and Relative Risk of Prostate Cancer: A Meta-analysis.

Authors:  Lin Yang; Shuanghua Xie; Xiaoshuang Feng; Yuheng Chen; Tongzhang Zheng; Min Dai; Cindy Ke Zhou; Zhibin Hu; Ni Li; Dong Hang
Journal:  Sci Rep       Date:  2015-10-06       Impact factor: 4.379

5.  Human papillomavirus 16 infection as a potential risk factor for prostate cancer: an adaptive meta-analysis.

Authors:  Jong-Myon Bae
Journal:  Epidemiol Health       Date:  2015-02-11

6.  MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer.

Authors:  Li Xue; Xiujuan Han; Rongrong Liu; Ziming Wang; Hecheng Li; Qi Chen; Peng Zhang; Zhenlong Wang; Tie Chong
Journal:  Oncotarget       Date:  2016-05-31

7.  Lack of evidence of HPV etiology of prostate cancer following radical surgery and higher frequency of the Arg/Pro genotype in Turkish men with prostate cancer.

Authors:  Merve Aydin; Aliseydi Bozkurt; Aytekin Cikman; Baris Gulhan; Mehmet Karabakan; Aysun Gokce; Murat Alper; Murat Kara
Journal:  Int Braz J Urol       Date:  2017 Jan-Feb       Impact factor: 1.541

8.  Association between TP53 gene codon72 polymorphism and prostate cancer risk: A systematic review and meta-analysis.

Authors:  Pei-Zhen Han; De-Hong Cao; Xue-Ling Zhang; Zheng-Ju Ren; Qiang Wei
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

9.  Lack of detection of human papillomavirus DNA in prostate carcinomas in patients from northeastern Brazil.

Authors:  Ari P Araujo-Neto; Hygor Ferreira-Fernandes; Carolina M M Amaral; Lina G Santos; Antônio C Freitas; Jacinto C Silva-Neto; Juan A Rey; Rommel R Burbano; Benedito B da Silva; France K N Yoshioka; Giovanny R Pinto
Journal:  Genet Mol Biol       Date:  2016-03       Impact factor: 1.771

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.